LEVETIRACETAM 250 MG
LEVETIRACETAM : 250 MG · DIN 02407159 · JUBILANT GENERICS LIMITED
Health Canada status: APPROVED
What is LEVETIRACETAM?
LEVETIRACETAM 250 MG contains LEVETIRACETAM : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02407159, held by JUBILANT GENERICS LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 30-May-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02407159 |
|---|---|
| Brand name | LEVETIRACETAM |
| Generic / active ingredient | LEVETIRACETAM : 250 MG |
| Manufacturer | JUBILANT GENERICS LIMITED |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AX14 LEVETIRACETAM |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 30-May-2013 |
What can be used instead?
Other Canadian products sharing ATC code N03AX14 LEVETIRACETAM. 47 of 109 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-LEVETIRACETAM | 250 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02399776 |
| ACH-LEVETIRACETAM | 500 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02399784 |
| ACH-LEVETIRACETAM | 750 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02399792 |
| AG-LEVETIRACETAM | 250 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485192 |
| AG-LEVETIRACETAM | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485206 |
| AG-LEVETIRACETAM | 750 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485214 |
| APO-LEVETIRACETAM | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02285924 |
| APO-LEVETIRACETAM | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02285932 |
| APO-LEVETIRACETAM | 750 MG | TABLET | APOTEX INC | MARKETED | DIN 02285940 |
| AURO-LEVETIRACETAM | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02375249 |
Who else supplies LEVETIRACETAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVETIRACETAM appears in 1082 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.